You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFludiazepam
Accession NumberDB01567
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionFludiazepam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is a scheduled drug in the U.S., but is approved for use in Japan.
Structure
Thumb
Synonyms
7-chloro-5-(O-Fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one
Erispan
Fludiazepamum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ErispanSumitomo
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7F64A2K16Z
CAS number3900-31-0
WeightAverage: 302.731
Monoisotopic: 302.062218928
Chemical FormulaC16H12ClFN2O
InChI KeyROYOYTLGDLIGBX-UHFFFAOYSA-N
InChI
InChI=1S/C16H12ClFN2O/c1-20-14-7-6-10(17)8-12(14)16(19-9-15(20)21)11-4-2-3-5-13(11)18/h2-8H,9H2,1H3
IUPAC Name
7-chloro-5-(2-fluorophenyl)-1-methyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
Pharmacology
IndicationUsed for the short-term treatment of anxiety disorders.
Structured Indications Not Available
PharmacodynamicsFludiazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Fludiazepam accumulates primarily in the cortex and thalamus.
Mechanism of actionFludiazepam has similar action to diazepam, but binds with four times more affinity to benzodiazepine receptors than diazepam.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
potentiator
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
potentiator
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
potentiator
HumanP31644 details
Gamma-aminobutyric acid receptor subunit gamma-1Proteinyes
potentiator
HumanQ8N1C3 details
Gamma-aminobutyric acid receptor subunit gamma-2Proteinyes
potentiator
HumanP18507 details
Gamma-aminobutyric acid receptor subunit gamma-3Proteinyes
potentiator
HumanQ99928 details
Gamma-aminobutyric acid receptor subunit beta-1Proteinyes
potentiator
HumanP18505 details
Gamma-aminobutyric acid receptor subunit beta-2Proteinyes
potentiator
HumanP47870 details
Gamma-aminobutyric acid receptor subunit beta-3Proteinyes
potentiator
HumanP28472 details
Gamma-aminobutyric acid receptor subunit deltaProteinyes
potentiator
HumanO14764 details
Gamma-aminobutyric acid receptor subunit epsilonProteinyes
potentiator
HumanP78334 details
Gamma-aminobutyric acid receptor subunit piProteinyes
potentiator
HumanO00591 details
Gamma-aminobutyric acid receptor subunit rho-1Proteinyes
potentiator
HumanP24046 details
Gamma-aminobutyric acid receptor subunit rho-2Proteinyes
potentiator
HumanP28476 details
Gamma-aminobutyric acid receptor subunit rho-3Proteinyes
potentiator
HumanA8MPY1 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Fludiazepam is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Fludiazepam is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fludiazepam.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fludiazepam.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fludiazepam.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Ambroxol acefyllinate.Experimental
AminophyllineThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Aminophylline.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fludiazepam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fludiazepam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Azaperone.Vet Approved
AzelastineFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fludiazepam.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fludiazepam.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fludiazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fludiazepam.Approved, Investigational
BuprenorphineFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fludiazepam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fludiazepam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fludiazepam.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fludiazepam.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fludiazepam.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Fludiazepam.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fludiazepam.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fludiazepam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fludiazepam.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fludiazepam.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fludiazepam.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fludiazepam.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fludiazepam.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Fludiazepam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fludiazepam.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fludiazepam.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fludiazepam.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fludiazepam.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fludiazepam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fludiazepam.Approved
DesipramineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fludiazepam.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fludiazepam.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fludiazepam.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fludiazepam.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fludiazepam.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fludiazepam.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fludiazepam.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fludiazepam.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fludiazepam.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fludiazepam.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Fludiazepam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fludiazepam.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fludiazepam.Approved
DyphyllineThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fludiazepam.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Fludiazepam is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fludiazepam.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fludiazepam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fludiazepam.Approved
EthanolFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fludiazepam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fludiazepam.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fludiazepam.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fludiazepam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fludiazepam.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fludiazepam.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fludiazepam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Flibanserin.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fludiazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fludiazepam.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fludiazepam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fludiazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fludiazepam.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Fludiazepam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fludiazepam.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Fludiazepam is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fludiazepam.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fludiazepam.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fludiazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fludiazepam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fludiazepam.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fludiazepam.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fludiazepam.Approved
HyaluronidaseThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fludiazepam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Indalpine.Investigational, Withdrawn
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fludiazepam.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fludiazepam.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fludiazepam.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fludiazepam.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fludiazepam.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fludiazepam.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Fludiazepam.Approved
LofentanilThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fludiazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fludiazepam.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Fludiazepam is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fludiazepam.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fludiazepam.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fludiazepam.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fludiazepam.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Metaxalone.Approved
MethadoneFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fludiazepam.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fludiazepam.Approved
MethotrimeprazineFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fludiazepam.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fludiazepam.Approved
MetyrosineFludiazepam may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Mianserin.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fludiazepam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Investigational
MirtazapineFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fludiazepam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fludiazepam.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fludiazepam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fludiazepam.Approved
OpiumThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Fludiazepam can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fludiazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fludiazepam.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fludiazepam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fludiazepam.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fludiazepam.Approved
ParaldehydeFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fludiazepam.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fludiazepam.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fludiazepam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fludiazepam.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fludiazepam.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fludiazepam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fludiazepam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pomalidomide.Approved
PramipexoleFludiazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fludiazepam.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fludiazepam.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fludiazepam.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fludiazepam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fludiazepam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fludiazepam.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fludiazepam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Fludiazepam is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fludiazepam.Approved
RacloprideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fludiazepam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fludiazepam.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fludiazepam.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fludiazepam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Romifidine.Vet Approved
RopiniroleFludiazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fludiazepam.Approved
RotigotineFludiazepam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fludiazepam.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Fludiazepam is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Fludiazepam is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fludiazepam.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fludiazepam.Approved, Vet Approved
Sodium oxybateFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
StiripentolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fludiazepam.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fludiazepam.Approved
SuvorexantFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Fludiazepam can be increased when it is combined with Teduglutide.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fludiazepam.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetrodotoxin.Investigational
ThalidomideFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fludiazepam.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fludiazepam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fludiazepam.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fludiazepam.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fludiazepam.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fludiazepam.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fludiazepam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fludiazepam.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fludiazepam.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Fludiazepam is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fludiazepam.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fludiazepam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fludiazepam.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zolazepam.Vet Approved
ZolpidemFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fludiazepam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid taking with grapefruit juice.
References
Synthesis Reference

Yamamato, H., Inaba, S.,Okamoto, T., Hirohashi, T., Ishizumi, K., Yamamoto, M., Maruyama, l., Mori, K. and Kobayashi, T.; U.S. Patents 3,723,461; March 27, 1973; 3,828,027; August 6, 1974 and 3,925,364; December 9, 1975; all assigned to Sumitomo Chemical Co., Ltd.

General References
  1. Ishiwata K, Yanai K, Ido T, Miura-Kanno Y, Kawashima K: Synthesis and biodistribution of [11C]fludiazepam for imaging benzodiazepine receptors. Int J Rad Appl Instrum B. 1988;15(4):365-71. [PubMed:2855634 ]
  2. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
External Links
ATC CodesN05BA17
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9946
Caco-2 permeable+0.8567
P-glycoprotein substrateSubstrate0.6618
P-glycoprotein inhibitor IInhibitor0.5293
P-glycoprotein inhibitor IINon-inhibitor0.8532
Renal organic cation transporterInhibitor0.592
CYP450 2C9 substrateNon-substrate0.6724
CYP450 2D6 substrateNon-substrate0.9087
CYP450 3A4 substrateSubstrate0.8081
CYP450 1A2 substrateInhibitor0.7925
CYP450 2C9 inhibitorNon-inhibitor0.5446
CYP450 2D6 inhibitorNon-inhibitor0.8884
CYP450 2C19 inhibitorInhibitor0.5598
CYP450 3A4 inhibitorInhibitor0.5153
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5827
Ames testNon AMES toxic0.8792
CarcinogenicityNon-carcinogens0.817
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2719 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9953
hERG inhibition (predictor II)Non-inhibitor0.8236
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point218.5-219Yamamato, H., Inaba, S.,Okamoto, T., Hirohashi, T., Ishizumi, K., Yamamoto, M., Maruyama, l., Mori, K. and Kobayashi, T.; U.S. Patents 3,723,461; March 27, 1973; 3,828,027; August 6, 1974 and 3,925,364; December 9, 1975; all assigned to Sumitomo Chemical Co., Ltd.
logP2.75HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0144 mg/mLALOGPS
logP2.83ALOGPS
logP3.22ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)1.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.67 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity80.03 m3·mol-1ChemAxon
Polarizability29.45 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0uk9-2794000000-6f1a3e2e0783b2069f2fView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Halobenzene
  • Fluorobenzene
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. [PubMed:2857046 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:10 / Updated on August 17, 2016 12:23